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tus, body mass index and diabetes.  Results: After 10 years of 
follow-up, 635 men had a first CHD and 98 a first ischemic 
stroke event. Total cholesterol (total-C), high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), non-HDL-C, triglycerides, apolipoprotein (Apo) 
A1 and Apo B100, their ratios and lipoprotein (a) [Lp(a)] were 
all significantly predictive of future CHD. Associations with 
ischemic stroke followed the same trend as for CHD, but with 
lower strength, and none were statistically significant. How-
ever, none of the differences between the hazard ratios for 
CHD and for ischemic stroke were statistically significant. 
 Conclusions: In healthy, middle-aged men, total-C, HDL-C, 
LDL-C, non-HDL-C, triglycerides, Apo A1 and Apo B100, their 
ratios and Lp(a) are, if anything, weak predictors of ischemic 
stroke events over a 10-year period. 
 Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Aim: To compare within the same cohort the association of 
a large panel of lipids with the risk of incident coronary heart 
disease (CHD) and ischemic stroke events in participants of 
the Prospective Epidemiological Study of Myocardial Infarc-
tion.  Methods: In this binational (Northern Ireland and 
France) prospective cohort, we considered 9,711 men aged 
50–59 years free of CHD and stroke at baseline (1991–1993). 
The hazard ratios of each lipid marker for CHD and ischemic 
stroke events were estimated in separate Cox proportional 
hazard models adjusted for age, study center, systolic blood 
pressure, antihypertensive treatment, current smoking sta-
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 Introduction 
 Several large randomized controlled trials have shown 
that cholesterol-lowering statin therapy can significantly 
reduce the risk of both coronary heart disease (CHD) and 
ischemic stroke  [1–4] . While the link between lipids and 
CHD risk is firmly established  [5–7] , it is still unclear 
whether there is one between lipids and ischemic stroke 
 [8] . An association between lipids and ischemic stroke 
has been supported by some  [9–12] but not all observa-
tional studies  [13–17] , suggesting an apparent stroke par-
adox for lipids  [18] . To date, only one cohort study has 
jointly evaluated the association of several lipids with fu-
ture CHD and ischemic stroke events and has suggested 
that lipids were also predictive of future ischemic stroke 
but with lower strength compared to CHD. However, this 
study was conducted in women only  [10] . Therefore, we 
aimed to extend this previous analysis to compare, with-
in the same cohort of European, middle-aged, male par-
ticipants of the Prospective Epidemiological Study of 
Myocardial Infarction (PRIME), the relative contribu-
tion of a large panel of circulating lipid markers to the 
occurrence of CHD and ischemic stroke events as the 
first presentation of cardiovascular disease.
 Methods 
 Study Population 
 The PRIME Study is a multicenter prospective cohort study 
designed to identify risk factors for CHD. Details of recruitment 
and the baseline examination of the PRIME Study have been de-
scribed previously  [19] . The target study size was to recruit 2,500 
men aged 50–59 years in each of the 4 collaborating World Health 
Organization (WHO) Monitoring Trends and Determinants in 
Cardiovascular Disease (MONICA) centers in Belfast (Northern 
Ireland), Lille, Strasbourg and Toulouse (France). Overall, 10,602 
men aged 50–59 years were recruited between 1991 and 1993. 
Among them, 823 had coronary disease and 77 a history of stroke 
at baseline examination and were excluded from the present anal-
ysis, leaving a study population of 9,711 men (7,319 in France and 
2,392 in Northern Ireland). 
 Baseline Examination 
 General Characteristics 
 Subjects who agreed to participate in the study were given a 
morning appointment and asked to fast for at least 12 h. A full 
description of clinical and laboratory measurements has been 
published elsewhere  [19] . Briefly, a self-administered health ques-
tionnaire was completed by subjects at their home and was subse-
quently checked by trained interviewers at the clinic. It covered a 
broad range of clinical information including family and person-
al clinical history using the Rose Questionnaire, alcohol con-
sumption, cigarette smoking and medication use. Diabetes was 
defined as the current intake of oral hypoglycemic treatment or 
use of insulin. Blood pressure was measured with the patient in 
the sitting position using the same automatic device (Spengler 
SP9, Spengler, Cachan, France). A 12-lead electrocardiogram was 
also recorded. 
 Biological Measurements 
 A subset of biological measurements was performed in the en-
tire cohort at baseline after overnight fasting. Plasma lipid analy-
ses were centralized (SERLIA INSERM U325, Institut Pasteur de 
Lille, France). Total cholesterol (total-C) was measured by enzy-
matic methods using commercial kits in an automatic analyzer 
(Boehringer, Mannheim, Germany). High-density lipoprotein 
cholesterol (HDL-C) was determined by enzymatic methods 
(Boehringer) after precipitation of apolipoprotein B-containing 
lipoproteins. Low-density lipoprotein cholesterol (LDL-C) was 
calculated according to the Friedewald formula for triglycerides 
 ^  4.5 g/l. Non-HDL-C was calculated using the following equa-
tion: non-HDL-C = total-C – HDL-C. Apolipoprotein (Apo) A1 
and Apo B100 were quantified using commercial reagent immu-
nonephelometry (Behringwerke, Marburg, Germany). Lipopro-
tein (a) [Lp(a)] was measured by a selective bi-site immunoenzy-
matic assay as previously described  [20] .
 The number of men with missing lipid measurements was as 
follows: total-C, n = 44 (0.45%); HDL-C, n = 47 (0.48%); Apo A1, 
n = 45 (0.46%); Apo B100, n = 45 (0.47%), and Lp (a), n = 50 (0.51%).
 Follow-Up and Ascertainment of Cases 
 During the 10-year follow-up, subjects were contacted annu-
ally by letter and asked to complete a clinical event questionnaire. 
For all subjects who reported a possible event, clinical informa-
tion was sought directly from the hospital or general practitioner 
records. All details of electrocardiograms, computerized tomo-
densitometry scans, hospital admissions, cardiac enzymes, surgi-
cal intervention, angioplasty, angiography and treatments were 
collected. For deceased patients, the circumstances of death were 
obtained from the practitioner or the family whenever possible. 
In the few cases where the circumstances surrounding the death 
were not available from the practitioner or the family, death cer-
tificates were checked for supporting clinical and postmortem in-
formation on the cause of death. 
 Incident CHD and ischemic stroke events were validated by 
two independent medical committees. CHD events (stable and 
unstable angina, myocardial infarction and coronary death) were 
defined as previously described using clinical, biological, stress 
test, scintigraphic or angiographic criteria  [19] . 
 Stroke was defined according to the WHO MONICA criteria 
 [21] as a new focal or global neurologic deficit of rapid onset and 
of vascular origin that persisted for more than 24 h (except if the 
symptoms were interrupted by a surgical intervention or a death). 
Transient ischemic attacks and strokes caused by a blood disease, 
a cerebral tumor or metastasis or secondary to a trauma were not 
considered by the stroke medical committee. 
 Clinical information, computerized tomodensitometry scans 
(compatible signs) and angiographic and autopsy data were used 
to evaluate and distinguish ischemic from hemorrhagic (sub-
arachnoid or intracerebral hemorrhage) stroke events. After 10 
years of follow-up, the CHD and ischemic stroke event status was 
available for 95.1% of the cohort. The 4.9% of men with unknown 
CHD and ischemic stroke event status had lower total-C, LDL-C, 
HDL-C and Apo A1 levels, higher Lp(a) and body mass index and 
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were more frequently current smokers compared to those in 
whom the status was known. 
 The study protocol was approved by the institutional review 
board of Broussais Hospital, Paris, France. Informed consent was 
obtained for each man who agreed to participate in the PRIME 
Study.
 Statistical Analysis 
 Baseline characteristics in the groups of men who remained 
free of CHD or ischemic stroke events during the follow-up, men 
who developed a CHD event and men who developed an ischemic 
stroke event were compared using Pearson   2 tests for categorical 
variables and ANOVA or the Kruskal-Wallis test for continuous 
variables, as appropriate. To account for multiple testing (n = 12 
comparisons of lipid risk factors), a Bonferroni correction was ap-
plied and a p value  ! 0.004 indicated a statistically significant dif-
ference. Post hoc pair-wise comparisons of lipid risk factors be-
tween men who developed a CHD event and men who developed 
an ischemic stroke event were performed using the Scheffé test. 
The associations of each lipid parameter with future CHD and 
ischemic stroke were estimated in separate Cox proportional haz-
ards models. Hazard ratios and their 95% confidence intervals 
(CIs) were given for 1 SD increase in the lipids calculated in men 
who remained free of clinical events during the follow-up. Analy-
sis was systematically adjusted for study center, age, systolic blood 
pressure, antihypertensive treatment, current smoking status, 
body mass index and diabetes on an a priori basis. For the 20 men 
who suffered from both a CHD and an ischemic stroke event dur-
ing follow-up, only the first event was considered for analysis; this 
group consisted of 12 men with first CHD events and 8 with first 
ischemic stroke events, respectively. In fact, when the occurrence 
of a stroke event prior to a CHD event or vice versa was taken into 
account using the competing risk method (the data-augmented 
method)  [22] , similar results were obtained. All comparisons were 
two-sided. All statistical analyses were performed using Stata 
software version 9.1 TM (StataCorp, College Station, Tex., USA).
 Results 
 The mean age of the 9,711 men was 54.7  8 2.9 years. 
After 10 years of follow-up, 635 men had a first CHD 
event (408 in France and 227 in Northern Ireland) and 
122 had a first stroke, including 98 of ischemic origin (64 
in France and 34 in Northern Ireland), 18 of hemorrhag-
ic origin and 6 of undetermined origin. First CHD and 
ischemic stroke occurred a median of 5.0 years (inter-
quartile range 2.8–7.8) and 5.4 years (interquartile range 
2.7–7.6), respectively, after baseline examination. 
 Table 1 compares the non-lipid characteristics of those 
men who remained free of CHD and ischemic stroke
(n = 8,978), those who developed a CHD event (n = 635) 
and those who had an ischemic stroke event (n = 98) dur-
ing follow-up. As expected, men who had a clinical event 
(CHD or ischemic stroke) had a significantly worse car-
diovascular risk profile than those who remained free of 
clinical events. Diabetes was twice as frequent in men 
with future ischemic stroke as in men with future CHD 
(p = 0.045). The mean systolic blood pressure (p = 0.48), 
antihypertensive treatment use (p = 0.65) and aspirin use 
(p = 0.85) were not statistically different between those 
with future ischemic stroke and those with future CHD. 
 Table 2 compares the mean levels of single lipids, lipid 
ratios and lipid-lowering treatment use between the 3 
groups defined above using a Bonferroni correction that 
accounted for multiple testing. Whereas the proportion 
of men on lipid-lowering treatment, and statins in par-
ticular, did not differ between the groups, lipid levels were 
on average significantly higher in men who developed 
Table 1.  Baseline non-lipid risk factors according to the clinical event developed during 10 years of follow-up in 
the PRIME Study
No incident clinical 







Age, years 54.882.88 55.382.93 55.683.01 <0.001
Current smoker, % 26.8 (2,410) 36.4 (231) 40.8 (40) <0.001
Systolic blood pressure, mm Hg 133.0818.5 140.8821.1 142.5822.3 <0.001
Diastolic blood pressure, mm Hg 83.5811.5 87.0812.5 87.0814.0 <0.001
Antihypertensive treatment, % 8.8 (761) 15.5 (92) 17.4 (16) <0.001
Aspirin, % 3.4 (308) 2.3 (15) 2.0 (2) 0.23
Body mass index 26.583.4 27.383.6 26.984.0 <0.001
Diabetes, % 2.0 (180) 4.4 (28) 9.2 (9) <0.001
D ata are means 8 SD and percentages (numbers in parentheses) for continuous and categorical vari -
ables, respectively. p values are the results of global comparison across the 3 groups using Pearson 2 test and 
ANOVA for categorical and continuous variables, respectively.
 Lipids, Coronary Heart Disease and 
Stroke 
Cerebrovasc Dis 2010;30:252–259 255
CHD or ischemic stroke compared to those who did not 
experience an incident clinical event. Moreover, the mean 
level of non-HDL-C, Apo B100, Lp(a) and each lipid ratio 
was higher and that of HDL-C lower in men with future 
CHD than in men with future ischemic stroke events, al-
though the difference was statistically significant for the 
Apo B100 to Apo A1 ratio only. 
 The multivariate associations of total-C, HDL-C, 
LDL-C, non-HDL-C, triglycerides, Apo A1, Apo B100 
and Lp(a) with future CHD and ischemic stroke are 
shown in  figure 1 . These lipids were all highly predictive 
of CHD, with comparable magnitude. Associations with 
ischemic stroke followed the same trend as for CHD, but 
were of lower strength, and none were statistically sig-
nificant. However, formal comparison between the haz-
ard ratios for CHD and ischemic stroke did not reach sta-
tistical significance.
 The multivariate associations of lipid ratios, including 
total-C/HDL-C, LDL-C/HDL-C, Apo B100/Apo A1 and 
Apo B100/HDL-C, with CHD and ischemic stroke events 
are shown in  figure 2 . As for single lipids, lipid ratios were 
all predictive of CHD, and the associations were of com-
parable magnitude. None of the studied lipid ratios was 
significantly associated with ischemic stroke events. The 
magnitude of their association with ischemic stroke was 
smaller than that for CHD. As for single lipids, however, 
none of the pair-wise comparisons between the hazard 
ratios for CHD and for ischemic stroke reached statistical 
significance. Further adjustment for baseline lipid-lower-
ing treatment did not substantially change the results of 
the multivariate analyses reported in  figures 1 and  2 (not 
shown). Among the non-lipid cardiovascular risk factors, 
systolic blood pressure, current smoking status and dia-
betes were the other independent predictors of ischemic 
stroke. For instance, in a model evaluating the predictive 
value of total-C, the corresponding hazard ratios were 
1.42 (95% CI 1.16–1.73; p = 0.001) for 1 SD increase in sys-
tolic blood pressure, 1.86 (95% CI 1.10–3.12; p = 0.02) for 
current smoking and 4.59 (95% CI 2.18 –9.67; p  ! 0.001) 
for diabetes. 
 Additional Analyses 
 In the PRIME Study, there was an attempt to classify 
incident ischemic stroke by subtypes. The 98 first isch-
emic stroke events included 39 lacunar infarctions, 27 
cardioembolic infarctions, 14 atherothrombotic infarc-
tions and 18 nonlacunar, noncardioembolic and nonath-
erothrombotic infarctions. In a sensitivity analysis in 
 Table 2. Baseline levels of lipid markers, lipid ratios and lipid-lowering treatment use according to the clinical event developed during 
the 10 years of follow-up in the PRIME Study
No incident c linical









Total-C, g/l 2.2180.38 2.3380.39 2.2780.41 <0.001 0.30
HDL-C, g/l 0.4980.13 0.4580.12 0.4880.13 <0.001 0.11
LDL-C, g/l 1.4380.33 1.5480.35 1.4880.37 <0.001 0.25
Non-HDL-C, g/l 1.7280.38 1.8880.40 1.7980.44 <0.001 0.08
Apo A1, g/l 1.5080.25 1.4280.23 1.4680.23 <0.001 0.28
Apo B100, g/l 1.2680.33 1.4180.37 1.3380.35 <0.001 0.08
Median Lp(a), mg/dl (25th–75th percentile) 6.5 (2.1–20) 9.8 (3–30) 6.6 (1.7–20) <0.001 0.073
Triglycerides, g/l 1.4681.0 1.7681.16 1.7081.09 <0.001 0.72
Total-C/HDL-C ratio 4.8081.54 5.5481.69 5.1381.78 <0.001 0.052
LDL-C/HDL-C ratio 3.1181.13 3.6481.30 3.3481.38 <0.001 0.065
Apo B100/Apo A1 ratio 0.8780.27 1.0280.31 0.9480.31 <0.001 0.021
Apo B100/HDL-C ratio 2.8281.32 3.4481.49 3.1281.48 <0.001 0.08
Lipid-lowering treatment, % 8.4 (750) 9.8 (62) 9.2 (9) 0.45 –
Ex cept for Lp(a), data are means 8 SD and percentages (numbers in parentheses) for continuous and categorical variables, respec-
tively. 
1 Global comparison across the 3 groups using Pearson 2 test and ANOVA or the Kruskal-Wallis test for categorical and continu-
ous variables, respectively; a Bonferroni correction was applied and a p value <0.004 indicated a statistically significant difference. 
2 Post hoc pair-wise comparisons between men with CHD and men with ischemic stroke events using the Scheffé test. Triglycerides 
were log-transformed for statistical analysis.
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which cardioembolic strokes were excluded (lipids may 
not be related to this subtype), there was still no signifi-
cant association between lipids and ischemic stroke in 
Cox models adjusted for age, study center and systolic 
blood pressure (not shown). 
 Discussion 
 The present population-based study of healthy Euro-
pean middle-aged men suggested that total-C, HDL-C, 
LDL-C, non-HDL-C, triglycerides, Apo A1 and Apo 
B100, their ratios and Lp(a) were weak predictors of isch-
emic stroke events over 10 years compared to their robust 
association with CHD events. However, it should be not-
ed that none of the differences between the hazard ratios 
of lipids for CHD and for ischemic stroke was statisti-
cally significant. 
 The strong association between lipids and CHD in the 
current study is consistent with the well-established link 
between lipids and CHD  [5–7] . There is an ongoing de-
bate as to which lipid variables are the best predictors of 
future CHD. Apolipoproteins and the Apo B100/Apo A1 
ratio have been advocated recently in some  [23, 24] but 
not all studies  [25, 26] . In our study, single lipids and apo-
lipoproteins and their corresponding ratios were associ-
ated with CHD, with the same order of magnitude over 
10 years.
 Most previous observational studies have investigat-
ed the association between 1 or 2 single lipid markers 
and ischemic stroke and have reported mixed results. 
Independent associations were found in a prospective 
Korean cohort  [9] and in a US case-control study  [12] , 
but not in 4 large population-based prospective studies 
 [14–17] . Furthermore, in 2 recent meta-analyses of indi-
vidual data, a weak positive association between total-C 
and ischemic stroke mortality was found only in the 
middle-aged subjects (40–59 years) or in those who were 
normotensive  [5] , while no association was observed be-
tween HDL-C and incident stroke of any type in Asians 
 [27] .
 To date, only one study conducted in US participants 
in the Women’s Health Study (WHS) has assessed the 
contribution of a large panel of lipids to both incident 
ischemic stroke and CHD events  [10] . In that study, in-
cluding 15,632 healthy women, of whom 132 developed 
Hazard ratio (95% CI)
0 0.5 1.0 1.5 2.0











Apo B100/Apo A1 
Apo B100/HDL-C 
CHD (n = 635) Ischemic stroke (n = 98) 
Hazard ratio (95% CI)
0 0.5 1.0 1.5 2.0
 Fig. 1. Standardized adjusted hazard ratios and 95% CIs of single 
lipids for CHD and ischemic stroke. Hazard ratios of each lipid 
variable were estimated in separate Cox proportional hazard re-
gression models adjusted for study center, age, systolic blood pres-
sure, antihypertensive treatment, body mass index, diabetes and 
smoking status. Triglycerides were log-transformed. 
 Fig. 2. Standardized adjusted hazard ratios and 95% CIs of lipid 
ratios for CHD and ischemic stroke. Hazard ratios of each lipid 
variable were estimated in separate Cox proportional hazard re-
gression models adjusted for study center, age, systolic blood pres-
sure, antihypertensive treatment, body mass index, diabetes and 
smoking status. 
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a first ischemic stroke over 10 years of follow-up, total-
C, HDL-C, non-HDL-C and LDL-C/HDL-C and total-
C/HDL-C ratios were predictive of ischemic stroke, 
whereas LDL-C, Apo A1, Apo B 100 and Apo B100/
HDL-C and Apo B100/Apo A1 ratios were not. The as-
sociations with ischemic stroke were weaker than those 
for CHD risk.  
 We have complemented the results of the WHS by 
conducting an analysis in men and by additionally in-
vestigating Lp(a). Consistent with the results of the 
WHS, we found that associations between lipids and 
ischemic stroke followed the same trend as those for 
CHD but were of lower magnitude. Contrary to the 
above study, however, none of the lipids investigated in 
our study were significantly associated with ischemic 
stroke. Three main factors may explain why we failed to 
observe any significant association between lipids and 
incident ischemic stroke events in the current study. 
Firstly, we may have had insufficient statistical power to 
detect true but smaller associations between lipids and 
ischemic stroke in men. However, similar negative find-
ings were described in men in cohorts with a higher in-
cidence of ischemic stroke events, namely the Physi-
cian’s Health Study (296 ischemic stroke events in 22,071 
men followed up for 11.5 years)  [14] and the Atheroscle-
rosis Risk in Communities Study (161 incident ischemic 
stroke events in more than 6,000 men followed up for 10 
years)  [15] . Secondly, ischemic stroke represents a het-
erogeneous condition, and the association of lipids with 
ischemic stroke, if any, may vary according to ischemic 
stroke subtype. Accordingly, total-C, LDL-C and HDL-
C have been shown to be more likely associated with 
atherothrombotic infarctions than with cardioembolic 
or lacunar infarctions  [11, 12, 28] . Although investigated 
in a relatively small number of stroke events, we found 
that lipids were not associated with ischemic strokes 
when cardioembolic strokes were excluded in the pres-
ent study. Thirdly, lipids might be associated with isch-
emic stroke in women but not in men (gender interac-
tion), as suggested by the results of the EUROSTROKE 
collaborative project for HDL-C  [13] and by those of the 
Atherosclerosis Risk in Communities study for triglyc-
erides and Apo B100, respectively  [15] . However, as we 
examined only men, this hypothesis could not be ex-
plored here.
 Moreover, our data indicated that Lp(a) was not asso-
ciated with ischemic stroke. A recent review of observa-
tional studies suggested that Lp(a) was an independent 
predictor of stroke of any type  [29] , but this review in-
cluded transient ischemic attack, contrary to our study. 
 Taken together, previous and current findings sug-
gest that the significantly reduced risk of ischemic stroke 
among subjects taking statin therapy observed in ran-
domized controlled trials might be due to non-choles-
terol or pleiotropic effects, possibly an anti-inflamma-
tory effect  [30–32] , although this issue has been debated 
 [33] . 
 The strengths of the current study include its prospec-
tive design, the use of standardized criteria to define clin-
ical events within the same population and the investiga-
tion of a large panel of lipids. However, the study does 
have some limitations that should be mentioned. As not-
ed above, our study may have lacked statistical power to 
detect a true but small association of lipids with ischemic 
stroke events. LDL-C is a heterogeneous group of parti-
cles varying in size, and small dense LDL particles have 
recently been found to be associated with an increased 
risk of first-ever stroke of thrombotic and hemorrhagic 
origin  [34] . However, small dense LDL particles were not 
measured in the PRIME Study. No interim examinations 
were performed in the PRIME Study, so that changes in 
lipid levels and in lipid-lowering treatment during follow-
up were not controlled for. The PRIME Study consisted 
of healthy middle-aged men, and thus the applicability of 
the current findings to women and elderly populations 
needs to be evaluated.
 Conclusion 
 The present population-based study suggests that cir-
culating lipids were weak predictors of ischemic stroke in 
healthy middle-aged men, contrasting with their robust 
association with CHD.
 Appendix 
 The PRIME Study Group 
 The PRIME Study is organized under an agreement between 
INSERM and the Merck, Sharp and Dohme-Chibret Laboratory, 
with the following participating laboratories:
 • The Strasbourg MONICA Project, Laboratoire d’Épidémio-
logie et de Santé Publique, EA 3430, Strasbourg, and Univer-
sité de Strasbourg, Strasbourg, France (D. Arveiler, B. Haas); 
 • The Toulouse MONICA Project, INSERM, U558, and Depart-
ment of Epidemiology, Université Paul Sabatier – Toulouse 
Purpan, Toulouse, France (J. Ferrieres, J.B. Ruidavets); 
 • The Lille MONICA Project, INSERM, U744, Lille, Institut 
Pasteur de Lille, Lille, and Université Lille Nord de France, 
Lille, France (P. Amouyel, M. Montaye); 
 • Department of Epidemiology and Public Health, Queen’s Uni-
versity, Belfast, UK (A. Evans, J. Yarnell, F. Kee); 
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 • Department of Atherosclerosis, INSERM, U545, Lille, Institut 
Pasteur de Lille, Lille, and Faculté de Médecine, Université 
Lille Nord de France, Lille, France (G. Luc, J.M. Bard); 
 • Laboratory of Hematology, INSERM, U626, Hôpital La Tim-
one, Marseille, France (I. Juhan-Vague, P. Morange); 
 • Laboratory of Endocrinology, INSERM, U563, Toulouse, 
France (B. Perret); 
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